| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0065-308X(08)60410-8 |
| P698 | PubMed publication ID | 8122565 |
| P2093 | author name string | Pépin J | |
| Milord F | |||
| P2860 | cites work | An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire | Q28273902 |
| Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids | Q28306157 | ||
| Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia | Q28334487 | ||
| Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia | Q28335915 | ||
| Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia | Q28361037 | ||
| Eflornithine Treatment of Refractory Pneumocystis carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome | Q33374197 | ||
| Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness | Q34048286 | ||
| Polyamine metabolism and function | Q34270606 | ||
| Present status of chemotheraphy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere | Q34532830 | ||
| Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense | Q35262080 | ||
| Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase | Q35268274 | ||
| Parasitic infections in women and their consequences | Q35669731 | ||
| Flow cytofluorimetric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense | Q36456619 | ||
| Trypanothione metabolism and rational approaches to drug design | Q37788203 | ||
| Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis | Q38025174 | ||
| Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination chemotherapy and African trypanosomiasis | Q38025175 | ||
| Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review | Q38220831 | ||
| A TRIAL OF MEL W IN THE TREATMENT OF TRYPANOSOMA RHODESIENSE SLEEPING SICKNESS. | Q38898554 | ||
| Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. | Q39255396 | ||
| The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire | Q39348731 | ||
| Existing chemotherapy and its limitations | Q39614669 | ||
| Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia | Q39764444 | ||
| Present status of chemotherapy and chemopropylaxis of human trypanosomiasis in the Eastern Hemisphere | Q40293568 | ||
| A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome | Q40741709 | ||
| Trypanosoma brucei: detection of low parasitaemias in mice by a miniature anion-exchanger/centrifugation technique | Q40842611 | ||
| The febrile response to treatment in Gambian sleeping sickness | Q40919542 | ||
| African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis | Q41160117 | ||
| Neurologic Complications Following the Treatment of Human Babesia Microti Infection with Diminazene Aceturate * | Q41928325 | ||
| Treatment with suramin and 2-substituted 5-nitroimidazoles of chronic murine Trypanosoma brucei infections with central nervous system involvement | Q42254423 | ||
| Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). | Q42854204 | ||
| Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-l-methionine | Q42860211 | ||
| Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya | Q43566679 | ||
| Suramin-induced polyneuropathy | Q43733268 | ||
| Investigations on mutagenicity and genotoxicity of pentamidine and some related trypanocidal diamidines | Q43982518 | ||
| Antagonism by polyamines of the curative effects of alpha-difluoromethylornithine in Trypanosoma brucei brucei infections | Q45213862 | ||
| Chemotherapy of trypanosomiasis: the potentiation of melarsoprol by concurrent difluoromethylornithine (DFMO) treatment | Q45294631 | ||
| Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease | Q46193271 | ||
| Four years' experience of melarsen oxide/BAL in the treatment of late-stage Rhodesian sleeping sickness | Q46210917 | ||
| The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. I. Reactions observed during treatment | Q46285654 | ||
| Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis | Q46346138 | ||
| The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol | Q46420986 | ||
| Suramin/metronidazole combination for African sleeping sickness | Q46537062 | ||
| Berenil in the treatment of Trypanosoma gambiense infection in man | Q46542859 | ||
| Nitrofurazone in the treatment of sleeping sickness due to Trypanosoma rhodesiense | Q46621300 | ||
| Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis | Q46813414 | ||
| High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire | Q46902652 | ||
| Late results of treatment of sleeping sickness in Sierra Leone by antrypol tryparsamide pentamidine and propamidine singly and in various combinations | Q46936357 | ||
| Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial | Q46949501 | ||
| The trypanocidal effect of drugs in different parts of the brain | Q48393120 | ||
| Human African trypanosomiasis (T.b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy | Q48402112 | ||
| Toxicity of beril in the dog | Q51162042 | ||
| Pharmacokinetics of diminazene in sheep. | Q52430846 | ||
| Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. | Q53856919 | ||
| Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. | Q53863471 | ||
| Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients. | Q53879692 | ||
| IgM and Antibody Measurement in the Diagnosis and Management of Gambian Trypanosomiasis | Q53988136 | ||
| Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients | Q54056659 | ||
| Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness | Q54131371 | ||
| Treatment of Rhodesian sleeping sickness in Kenya. | Q54348210 | ||
| Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. | Q55244580 | ||
| Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness | Q58844247 | ||
| Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness | Q58845433 | ||
| Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine | Q58846432 | ||
| New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin | Q58846914 | ||
| Polyamine metabolism: a potential therapeutic target in trypanosomes | Q58847872 | ||
| Pentamidine: Clinical pharmacologic correlations in man and mice | Q58849316 | ||
| Trypanosoma brucei: Suramin and other trypanocidal compounds' effects on sn-glycerol-3-phosphate oxidase | Q58850315 | ||
| Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man | Q58851137 | ||
| The chemoprophylaxis of sleeping sickness with the diamidines | Q58851495 | ||
| The therapeutic effect on a group of sleeping sickness patients of a single injection of 3854 R.P. (mel B Friedheim-arsobal Spécia) | Q58851535 | ||
| The treatment of advanced cases of Rhodesian sleeping sickness by Mel. B. and arsobal | Q58851636 | ||
| The efficacy of certain trypanocidal compounds against Trypanosoma gambiense infection in man | Q58851968 | ||
| Mel B in the treatment of human trypanosomiasis | Q58852144 | ||
| Pentamidine transport in Trypanosoma brucei—Kinetics and specificity | Q67448031 | ||
| Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program | Q67520489 | ||
| Pharmacokinetic investigations on diminazene and rolitetracycline in comparison to a combination of both | Q67872689 | ||
| Suramin awakes? | Q68128616 | ||
| Suramin Keratopathy | Q68461570 | ||
| Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS | Q68809529 | ||
| Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia | Q70247991 | ||
| Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase | Q71557183 | ||
| Further studies on the mode of action of arsenicals on trypanosome pyruvate kinase | Q72398233 | ||
| Estimation of the concentration of melarsoprol (Mel B) and Mel W in biological fluids by bioassay with trypanosomes in vitro | Q79516969 | ||
| Treatment of Sleeping Sickness in Sierra Leone | Q99759549 | ||
| Second Report on the Treatment of Trypanosomiasis by Pentamidine | Q99759706 | ||
| P921 | main subject | African trypanosomiasis | Q203133 |
| trypanosomiasis | Q2443552 | ||
| P304 | page(s) | 1-47 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Advances in Parasitology | Q15764504 |
| P1476 | title | The treatment of human African trypanosomiasis | |
| P478 | volume | 33 |
| Q28477104 | 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach |
| Q33294205 | 2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities |
| Q46243733 | A diminazene-resistant strain of Trypanosoma brucei brucei isolated from a dog is cross-resistant to pentamidine in experimentally infected albino rats |
| Q32020882 | A disubstituted NAD+ analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase |
| Q30883740 | A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. |
| Q28366780 | Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design |
| Q46891456 | African Trypanosomiasis: Changing Epidemiology and Consequences |
| Q28256727 | African trypanosomiasis: sensitive and rapid detection of the sub-genus Trypanozoon by loop-mediated isothermal amplification (LAMP) of parasite DNA |
| Q50099513 | An agent-based model of tsetse fly response to seasonal climatic drivers: Assessing the impact on sleeping sickness transmission rates |
| Q28306793 | An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei |
| Q56892210 | Anti-sleeping Sickness Drugs and Cancer Chemotherapy |
| Q39559177 | Antiparasitic effects of the intra-Golgi transport inhibitor megalomicin |
| Q39907314 | Antiplasmodial and antitrypanosomal activity of plants from the Kingdom of Saudi Arabia |
| Q58828774 | Antiprotozoal drugs |
| Q39864246 | Antitrypanosomal activity of some pregnane glycosides isolated from Caralluma species |
| Q37390578 | Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis |
| Q36079376 | Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes |
| Q35126182 | Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis |
| Q53682355 | Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. |
| Q38887204 | Bioassay-guided isolation of a diastereoisomer of kolavenol from Entada abyssinica active on Trypanosoma brucei rhodesiense |
| Q58842210 | Brain-Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis |
| Q40373900 | Brucellosis presenting as pyrexia of unknown origin in an international traveller: a case report |
| Q31447553 | Characterisation of the antitrypanosomal activity of peptidyl alpha-aminoalkyl phosphonate diphenyl esters. |
| Q34298863 | Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis |
| Q46540128 | Characterization of the novel Trypanosoma brucei inosine 5'-monophosphate dehydrogenase |
| Q24201785 | Chemotherapy for second-stage Human African trypanosomiasis |
| Q24236290 | Chemotherapy for second-stage Human African trypanosomiasis |
| Q35569065 | Chemotherapy of human African trypanosomiasis: current and future prospects |
| Q52595328 | Chemotherapy of human african trypanosomiasis. |
| Q24244635 | Chemotherapy of second-stage Human African trypanosomiasis |
| Q34319076 | Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). |
| Q27680672 | Crystal structures of Trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes |
| Q34693208 | Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies |
| Q34131218 | Diagnostic accuracy of molecular amplification tests for human African trypanosomiasis--systematic review |
| Q34150973 | Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis |
| Q26999453 | Drug repurposing and human parasitic protozoan diseases |
| Q37317284 | Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story |
| Q42832217 | East African trypanosomiasis in a pregnant traveler |
| Q34111900 | Efficacy of Cymelarsan and Diminasan against Trypanosoma equiperdum infections in mice and horses |
| Q33900237 | Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial |
| Q37728108 | Emerging trends in the diagnosis of human African Trypanosomiasis |
| Q39294611 | Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model |
| Q33526674 | Exocytosis and protein secretion in Trypanosoma. |
| Q57692156 | Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor |
| Q35793486 | Exploiting Human Resource Requirements to Infer Human Movement Patterns for Use in Modelling Disease Transmission Systems: An Example from Eastern Province, Zambia |
| Q33636542 | Facile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma brucei |
| Q35345427 | From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study |
| Q34647009 | Genetic dissection of drug resistance in trypanosomes |
| Q38884977 | Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy |
| Q38870844 | High-throughput decoding of antitrypanosomal drug efficacy and resistance |
| Q34657072 | High-throughput decoding of drug targets and drug resistance mechanisms in African trypanosomes |
| Q33975416 | History of sleeping sickness in East Africa |
| Q35668843 | Human African trypanosomiasis of the CNS: current issues and challenges |
| Q36422889 | Human African trypanosomiasis-neurological aspects |
| Q36492717 | Human African trypanosomiasis: Epidemiology and control. |
| Q38940879 | Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy |
| Q36740553 | Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. |
| Q44209129 | Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen |
| Q33653056 | Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis |
| Q90504690 | Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity |
| Q28485372 | Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign |
| Q33680317 | Immunobiology of African trypanosomes: need of alternative interventions |
| Q42065086 | In Silico Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors. |
| Q39127478 | In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei |
| Q27305075 | In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis |
| Q37181321 | Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis |
| Q37075493 | Leishmania donovani ornithine decarboxylase is indispensable for parasite survival in the mammalian host |
| Q92313351 | Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola |
| Q26863285 | Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects |
| Q24645104 | Nucleic acid sequence-based amplification with oligochromatography for detection of Trypanosoma brucei in clinical samples |
| Q33990598 | Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488 |
| Q24557540 | Options for field diagnosis of human african trypanosomiasis |
| Q31151922 | Outcome of acute East African trypanosomiasis in a Polish traveller treated with pentamidine |
| Q39498814 | Phenolic Constituents of Medicinal Plants with Activity against Trypanosoma brucei. |
| Q39126784 | Physico-chemical properties of the trypanocidal drug melarsoprol |
| Q74154992 | Polyamine derivatives as inhibitors of trypanothione reductase and assessment of their trypanocidal activities |
| Q35207890 | Prevalence and types of coinfections in sleeping sickness patients in kenya (2000/2009). |
| Q39215623 | Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis |
| Q46318673 | Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin |
| Q38886219 | Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda |
| Q34589130 | Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study |
| Q27617894 | Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase |
| Q39020376 | Susceptibility Testing of Medically Important Parasites |
| Q34585708 | Targeting of toxic compounds to the trypanosome's interior |
| Q37123713 | The Trypanosoma brucei gambiense secretome impairs lipopolysaccharide-induced maturation, cytokine production, and allostimulatory capacity of dendritic cells |
| Q33976793 | The anti-influenza virus drug rimantadine has trypanocidal activity |
| Q33632804 | The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes |
| Q35938334 | The epidemiology of trypanosomiasis in Rumphi district, Malawi: a ten year retrospective study. |
| Q56892222 | The fall and rise of sleeping sickness |
| Q58854998 | The proteasome as a potential target for chemotherapy of African trypanosomiasis |
| Q43229169 | The protozoan view of the human condition |
| Q34343084 | The role of molecular biology in veterinary parasitology |
| Q33973693 | The trypanosomiases. |
| Q56892186 | Transport of methionine in Trypanosoma brucei brucei |
| Q34240091 | Transporters in African trypanosomes: role in drug action and resistance |
| Q37328224 | Traversal of human and animal trypanosomes across the blood-brain barrier |
| Q35946968 | Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness |
| Q34139907 | Treatment of human African trypanosomiasis--present situation and needs for research and development |
| Q36551049 | Treatment options for second-stage gambiense human African trypanosomiasis |
| Q27008593 | Trypanocidal activity of marine natural products |
| Q28477646 | Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads |
| Q37661154 | Trypanosomiasis and the brain |
| Q36009318 | Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. |
| Q34118095 | Uptake and mode of action of drugs used against sleeping sickness. |
| Q43793473 | Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter |
| Q56892198 | Uptake of the nitroimidazole drug megazol by African trypanosomes |
| Q46610326 | Veterinary link to drug resistance in human African trypanosomiasis? |
Search more.